Skip to main content
Cardiosense Recieves FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure Read the press release

Media Coverage

Cardiosense Wins FDA De Novo Nod for PCWP Analysis Software

Keep reading